DE69130113D1 - Proteine mit geänderten epitopen und verfahren zur deren herstellung - Google Patents

Proteine mit geänderten epitopen und verfahren zur deren herstellung

Info

Publication number
DE69130113D1
DE69130113D1 DE69130113T DE69130113T DE69130113D1 DE 69130113 D1 DE69130113 D1 DE 69130113D1 DE 69130113 T DE69130113 T DE 69130113T DE 69130113 T DE69130113 T DE 69130113T DE 69130113 D1 DE69130113 D1 DE 69130113D1
Authority
DE
Germany
Prior art keywords
epitopes
proteins
changed
production
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69130113T
Other languages
English (en)
Other versions
DE69130113T2 (de
Inventor
Uffe Loevborg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205875&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69130113(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE69130113D1 publication Critical patent/DE69130113D1/de
Application granted granted Critical
Publication of DE69130113T2 publication Critical patent/DE69130113T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38627—Preparations containing enzymes, e.g. protease or amylase containing lipase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38645—Preparations containing enzymes, e.g. protease or amylase containing cellulase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38654—Preparations containing enzymes, e.g. protease or amylase containing oxidase or reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
DE69130113T 1990-12-05 1991-12-05 Proteine mit geänderten epitopen und verfahren zur deren herstellung Revoked DE69130113T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90610072 1990-12-05
PCT/DK1991/000382 WO1992010755A1 (en) 1990-12-05 1991-12-05 Proteins with changed epitopes and methods for the production thereof

Publications (2)

Publication Number Publication Date
DE69130113D1 true DE69130113D1 (de) 1998-10-08
DE69130113T2 DE69130113T2 (de) 1999-05-12

Family

ID=8205875

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69130113T Revoked DE69130113T2 (de) 1990-12-05 1991-12-05 Proteine mit geänderten epitopen und verfahren zur deren herstellung

Country Status (11)

Country Link
EP (1) EP0561907B1 (de)
JP (3) JP3355186B2 (de)
KR (1) KR100237968B1 (de)
AT (1) ATE170630T1 (de)
AU (1) AU9052891A (de)
BR (1) BR9107206A (de)
CA (2) CA2095852C (de)
DE (1) DE69130113T2 (de)
DK (1) DK0561907T3 (de)
FI (1) FI932561A (de)
WO (1) WO1992010755A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002618A1 (en) * 1992-07-17 1994-02-03 Gist-Brocades N.V. High alkaline serine proteases
AU3599895A (en) * 1994-10-14 1996-05-06 Chiron Mimotopes Pty Ltd Method and apparatus for efficient mimotope discovery
JP2001511162A (ja) * 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
CA2325568A1 (en) * 1998-03-26 1999-09-30 The Procter & Gamble Company Serine protease variants having amino acid substitutions
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
KR20010052223A (ko) * 1998-03-26 2001-06-25 데이비드 엠 모이어 아미노산 결실 및 치환을 갖는 세린 프로테아제 변이체
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6838269B1 (en) * 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6461849B1 (en) * 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
WO2000026230A1 (en) * 1998-10-30 2000-05-11 Novozymes A/S Low allergenic protein variants
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
AU5928100A (en) * 1999-07-22 2001-02-13 Procter & Gamble Company, The Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
JP2003505070A (ja) 1999-07-22 2003-02-12 ザ、プロクター、エンド、ギャンブル、カンパニー 定められたエピトープ領域においてアミノ酸置換を有するサブチリシンプロテアーゼ変異体
CA2379723A1 (en) * 1999-07-22 2001-02-01 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
EP1196548A2 (de) 1999-07-22 2002-04-17 The Procter & Gamble Company Proteasekonjugaten mit sterisch geschützten hydrolysierbaren stellen
CZ2002210A3 (cs) * 1999-07-22 2002-05-15 The Procter & Gamble Company Proteasa podobající se subtilisinu obsahující intramolekulární zesí»ování a její pouľití
ATE471377T1 (de) * 2000-04-28 2010-07-15 Novozymes As Variante eines lipolytischen enzyms
ATE307882T1 (de) 2000-07-28 2005-11-15 Henkel Kgaa Neues amylolytisches enzym aus bacillus sp. a 7-7 (dsm 12368) sowie wasch- und reinigungsmittel mit diesem neuen amylolytischen enzym
DE60144399D1 (de) * 2000-10-02 2011-05-19 Danisco Us Inc Methode zur bestimmung der immunogenität von proteinen, die eine veränderte immunantwort hervorrufen
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US6929939B2 (en) 2001-03-23 2005-08-16 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20050020494A1 (en) * 2001-09-04 2005-01-27 Carr Francis J Modified human growth hormone
EP1461072A4 (de) * 2001-12-31 2005-02-09 Genencor Int Eine veränderte immunologische reaktion hervorrufende proteasen und herstellungs- und verwendungsverfahren dafür
JP2005535284A (ja) 2001-12-31 2005-11-24 ジェネンコー・インターナショナル・インク 免疫反応の変化を生じるプロテアーゼ、ならびにその製造および利用方法
CN101177675B (zh) 2002-02-08 2014-05-21 诺维信公司 肌醇六磷酸酶变体
AU2003223934A1 (en) * 2002-05-16 2003-12-02 Alk Abello A/S Recombinant bet. v. 1. allergen mutants, methods and process thereof
CA2493361A1 (en) 2002-07-30 2004-02-05 Genencor International, Inc. Reduced aerosol generating formulations
US20040121953A1 (en) * 2002-08-09 2004-06-24 Chirino Arthur J. Thrombopoiesis-stimulating proteins having reduced immunogenicity
AU2003266941A1 (en) 2002-10-01 2004-04-23 Novozymes A/S Family gh 61 polypeptides
EP2500423B1 (de) 2003-02-26 2015-06-17 Danisco US Inc. Amylasen, die eine veränderte immunogene Reaktion bewirken, und Verfahren zu ihrer Herstellung und Verwendung
JP2006513709A (ja) 2003-02-26 2006-04-27 ジェネンコー・インターナショナル・インク 修飾されたアミラーゼ免疫反応を示すアミラーゼ変異体、及び、これらの製造方法並びに用途
US20060236414A1 (en) 2003-06-19 2006-10-19 Novozymes A/S Proteases and methods for producing them
ES2346654T3 (es) 2003-06-19 2010-10-19 Novozymes A/S Proteasas.
WO2005035747A1 (en) 2003-10-10 2005-04-21 Novozymes A/S Protease variants
PL1673398T3 (pl) 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
WO2005066339A2 (en) 2004-01-06 2005-07-21 Novozymes A/S Polypeptides of alicyclobacillus sp.
DK1706428T3 (da) 2004-01-22 2009-11-30 Merck Patent Gmbh Anti-cancer-antistoffer med reduceret komplementfiksering
EP1735433B1 (de) 2004-04-02 2010-12-08 Novozymes A/S Subtilasevarianten mit veränderter immunogenität
WO2005123911A2 (en) 2004-06-21 2005-12-29 Novozymes A/S Proteases
AR050895A1 (es) 2004-10-04 2006-11-29 Novozymes As Polipeptidos que tienen actividad de fitasa y polinucleotidos que los codifican
JP5221137B2 (ja) 2004-10-04 2013-06-26 ノボザイムス アクティーゼルスカブ フィターゼ活性を有するポリペプチド及びそれをコードするポリヌクレオチド
US8119387B2 (en) 2005-08-16 2012-02-21 Novozymes A/S Polypeptides of strain Bacillus sp. P203
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
WO2007067473A2 (en) 2005-12-06 2007-06-14 Genencor International, Inc. Perhydrolase epitopes
CN101370827B (zh) 2005-12-21 2015-10-14 麦克罗梅特股份公司 具有cea抗性的药物组合物
ES2384055T3 (es) 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada
JP2009521912A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された免疫原性を有する抗ｃｄ１９抗体
EP1998793A1 (de) 2006-03-22 2008-12-10 Novozymes A/S Verwendung von polypeptiden mit antimikrobieller wirkung
EP2001999B1 (de) 2006-04-04 2012-05-16 Novozymes A/S Phytasevarianten
WO2008079685A2 (en) 2006-12-21 2008-07-03 Novozymes A/S Lipase variants for pharmaceutical use
US8221743B2 (en) 2006-12-22 2012-07-17 Novozymes A/S Use of polypeptides against diseases caused by protozoans
EP2129781B1 (de) 2007-03-26 2014-01-22 Novozymes A/S Hafnia-phytase
EP2342323B1 (de) 2008-09-26 2013-06-05 Novozymes A/S Hafnia-phytasevarianten
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
EP2496257A4 (de) 2009-11-05 2013-02-27 Cephalon Australia Pty Ltd Behandlung von krebs mit mutierten kras- oder braf-genen
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
US20170269092A1 (en) 2014-12-02 2017-09-21 Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
AU2021324389A1 (en) 2020-08-13 2023-02-02 Novozymes A/S Phytase variants and polynucleotides encoding same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903068A (en) * 1972-12-26 1975-09-02 Us Health Education & Welfare Facile synthesis of human insulin by modification of porcine insulin
DK6488D0 (da) * 1988-01-07 1988-01-07 Novo Industri As Enzymer
DK316989D0 (da) * 1989-06-26 1989-06-26 Novo Nordisk As Enzymer

Also Published As

Publication number Publication date
WO1992010755A1 (en) 1992-06-25
FI932561A0 (fi) 1993-06-04
BR9107206A (pt) 1993-11-03
AU9052891A (en) 1992-07-08
JP2002101880A (ja) 2002-04-09
FI932561A (fi) 1993-06-04
KR100237968B1 (ko) 2000-01-15
EP0561907B1 (de) 1998-09-02
CA2331936C (en) 2007-07-31
CA2331936A1 (en) 1992-06-06
JP3450840B2 (ja) 2003-09-29
KR930703610A (ko) 1993-11-30
DE69130113T2 (de) 1999-05-12
CA2095852A1 (en) 1992-06-06
DK0561907T3 (da) 1999-05-31
JP2003174871A (ja) 2003-06-24
JPH06502994A (ja) 1994-04-07
JP3355186B2 (ja) 2002-12-09
ATE170630T1 (de) 1998-09-15
CA2095852C (en) 2001-05-08
EP0561907A1 (de) 1993-09-29

Similar Documents

Publication Publication Date Title
DE69130113D1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
ATE68826T1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
KR900009095A (ko) 합성 항원, 이의 제조방법 및 용도
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
DE69316405D1 (de) Verfahren zur fermentativen Herstellung von Aminosäuren
DE69406158D1 (de) Verfahren zur Herstellung von Olefinen mit endständigen Doppelbindungen
DE68919246D1 (de) Verfahren zur Herstellung von Aminosäuren.
DE69129899D1 (de) Verfahren zur Herstellung von D-Alpha-Aminosäuren
DE69220113D1 (de) Verfahren zur Herstellung von menschlichem Serum Albumin
DE59100547D1 (de) Verfahren zur Herstellung von linearen Polyamiden.
DE69332471D1 (de) Verfahren zur herstellung modifizierten proteine
DE68910771D1 (de) Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
DE68912734D1 (de) Verfahren zur Herstellung von Tetrafluoräthylen.
KR900012626A (ko) 하이브리드 단백질, 이의 생산방법 및 이를 함유하는 약제학적 조성물
DE68926922D1 (de) Verfahren zur Herstellung von L-alpha-Aminosäuren
DE68912885D1 (de) Verfahren zur Herstellung von L-Threonin.
DE3785119D1 (de) Verfahren zur herstellung von aminosaeuren.
ATA7285A (de) Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
DE3884324D1 (de) Verfahren zur Herstellung von menschlichen pro-apolipoprotein-A-I-ähnlichen Proteinen.
DE69530176T2 (de) Verfahren zur Herstellung von Protein
DE69431097D1 (de) Verfahren zur Herstellung von humanem Serumalbumin
ATE81013T1 (de) Verfahren zur herstellung von faktor viii:cmangelplasma und ein so erhaltenes mangelplasma.
DE3884261D1 (de) Verfahren zur Herstellung von Fremdproteinen in Streptomyceten.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: NOVOZYMES A/S, BAGSVAERD, DK

8331 Complete revocation